FDA recall D-0388-2025

Breckenridge Pharmaceutical, Inc · Class II · drug

Product

Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51991-747-90), b.) 1000-count bottles (NDC 51991-747-10), Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L. Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922

Reason for recall

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Distribution

US Nationwide.

Key facts

Status
Ongoing
Initiation date
2025-04-14
Report date
2025-04-30
Voluntary/Mandated
Voluntary: Firm initiated
Location
Berlin, CT, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0388-2025